News

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced entry into…
Read More...

OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD…
Read More...

Sun Pharmaceutical announced the successful completion of its acquisition of Concert Pharmaceuticals for the development of deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor,…
Read More...

Shorla Oncology (‘Shorla’) announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults and adolescents aged…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for LEQEMBI™…
Read More...

Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved a single-dose, prefilled autoinjector presentation of UDENYCA (pegfilgrastim-cbqv), a…
Read More...

Ipsen announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s…
Read More...

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen) today announced the launch of the…
Read More...

Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the…
Read More...

Avenue Therapeutics, Inc. announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. (“AnnJi”), a Taiwanese clinical-stage drug company, for…
Read More...

Chugai Pharmaceutical Co., Ltd. and Biofourmis announced that they have entered into a new partnership agreement for the continued development and real-world use of digital solutions to…
Read More...

Confo Therapeutic announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the…
Read More...

Nexus Pharmaceuticals, Inc. announced that it has received US Food and Drug Administration (FDA) approval for EMERPHED (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL…
Read More...

Oragenics, Inc. announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the…
Read More...

The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation…
Read More...

ImmunoGen, Inc. announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (Vertex) (NYSE: VRTX) rights to conduct research using…
Read More...

BioNxt Solutions Inc. is pleased to report that it has executed an agreement to carry out its comparative drug absorption study for the Company’s transdermal (“TDS”) Rotigotine patch…
Read More...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica (PMR),…
Read More...

Sunshine Biopharma Inc. announced the signing of an exclusive worldwide license agreement (the “License Agreement”) with the University of Arizona. The License Agreement grants Sunshine…
Read More...